Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses…

Background and Aims Portal hypertension (PHT) hepatocellular carcinoma (HCC) are major complication of cirrhosis which significantly contribute to morbidity mortality. In this review, we aim describe the consequences both angiogenesis inflammation in pathogenesis PHT HCC, but also difficulty propose adapted treatment when HCC coexist same patients. Methods Studies for review article were retrieved from PubMed database using literature published English until March 2021. Results occurs secondary an increase intrahepatic vascular resistances, opening portosystemic collateral vessels formation neovessels, related endothelial growth factor (VEGF). Recently, bacterial translocation-mediated was identified as a contributor PHT. Interestingly, VEGF chronic occurrence. As often patient, management its complications well appear more complex. Indeed, PHT-related such significant ascites may hamper access presence is independently associated with poor prognosis patients acute variceal bleeding Due their respective mechanism action, combination Atezolizumab Bevacizumab advanced impact level date, no real-life data available. Conslusions Appropriate evaluation remains issue order improve outcome